Latest Tyrosine kinase inhibitors Stories
NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer.
RnRMarketResearch.com adds “Nintedanib (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
MTD Confirmed in Combination with Topotecan, First Patient Dosed in Cohort Expansion SAN DIEGO, Oct. 29, 2014 /PRNewswire/ -- MEI Pharma, Inc.
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company.
ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- EntreMed, Inc.
SOUTH SAN FRANCISCO, Calif., Feb.
- totally perplexed and mixed up.